AstraZeneca Presents P-III Trial (NEURO-TTRansform) Results of Eplontersen for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy at AAN 2023
Shots:
- The P-III trial evaluating eplontersen vs PBO. The trial met all co-primary EPs & 2EPs @66wks. i.e., the therapy showed a consistent & sustained benefit on 3 co-1EPs of serum transthyretin (TTR) concentration, neuropathy impairment & QoL, LS mean reduction of 82% vs 11% in TTR serum concentration
- Eplontersen halted neuropathy disease progression resulting in a 0.28 vs 25.06 points LS mean increase, improvements in neuropathy & QoL (47% vs 17%) & (58% vs 20%) @66wks.; 53% vs 19% & 65% vs 23% among study completers, significant benefits on mNIS+7 & Norfolk QoL-DN @35wks. further improved @66wks.
- Improvement in all 2EPs along with favorable safety & tolerability profile, the rate of TEAEs was similar to PBO with no AEs led to study drug discontinuation
Ref: Businesswire | Image: AstraZeneca
Related News:- Ionis Reports the US FDA’s Acceptance of NDA for Eplontersen to Treat Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
